Keith Lane of Orange Clinical joins us to discuss the current state of gene therapy and its standardized endpoints, and the challenges gene therapy has faced, particularly in relation to ophthalmology.

S2 Ep3: The changing landscape of gene therapy and standardized endpoints

<div>Hosted by the award-winning editorial staff of <strong>Ophthalmology Times®</strong>, EyePod podcasts feature the latest updates and resources most relevant to professionals across the eyecare industry.</div>

Science

Life Sciences

Hosted by the award-winning editorial staff of Ophthalmology Times®, EyePod podcasts feature the latest updates and resources most relevant to professionals across the eyecare industry.

Hosted by the award-winning editorial staff of <strong>Ophthalmology Times®</strong>, EyePod podcasts feature the latest updates and resources most relevant to professionals across the eyecare industry.

Share S2 Ep3: The changing landscape of gene therapy and standardized endpoints

Sign up to save your podcasts

S2 Ep3: The changing landscape of gene therapy and standardized endpoints

S2 Ep3: The changing landscape of gene therapy and standardized endpoints